# Robert Bissonnette

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-bissonnette/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,029 |
| Field | Dermatology and Skin Diseases |
| h-index | 74 |
| i10-index | 231 |
| Last Known Institution | Innovaderm (Canada) |
| OpenAlex ID | https://openalex.org/A5029971595 |
| ORCID iD | https://orcid.org/0000-0001-5927-6587 |
| Works | 477 |

## Researcher papers

- [Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis](https://scholariq.org/papers/dupilumab-progressively-improves-systemic-and-cutaneous-abnormalities-in/)
- [Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial](https://scholariq.org/papers/topical-tofacitinib-for-atopic-dermatitis-a-phase-scp-ii-scp-a-randomized-trial/)
- [Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial](https://scholariq.org/papers/efficacy-and-safety-of-oral-alitretinoin-9-cis-retinoic-acid-in-patients-with/)
- [Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase<scp>III</scp>trials](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-and-inadequate/)
- [A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis](https://scholariq.org/papers/a-phase-2-trial-of-guselkumab-versus-adalimumab-for-plaque-psoriasis/)
- [Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study](https://scholariq.org/papers/dupilumab-shows-long-term-safety-and-efficacy-in-patients-with-moderate-to/)
- [IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis](https://scholariq.org/papers/il-4r-blockade-by-dupilumab-decreases-staphylococcus-aureus-colonization-and/)
- [Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-multiple-dupilumab-dose-regimens-after-initial-successful/)
- [Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)](https://scholariq.org/papers/baricitinib-in-patients-with-moderate-to-severe-atopic-dermatitis-results-from-a/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Psoriasis: Treatment and Pathogenesis](https://scholariq.org/topics/psoriasis-treatment-and-pathogenesis/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)

## Researcher university

- [Innovaderm (Canada)](https://scholariq.org/institutions/innovaderm-canada/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.